Production of HIV-1-based virus-like particles for vaccination: achievements and limits

Over the past years, much knowledge has been gained about the HIV-1 virus structure and infection cycle. This knowledge has been used to conceive different types of potential vaccines and vaccination strategies. This review focuses on the characteristics of the virus and the vaccines that have been...

Full description

Saved in:
Bibliographic Details
Published in:Applied microbiology and biotechnology 2019-09, Vol.103 (18), p.7367-7384
Main Authors: Cervera, Laura, Gòdia, Francesc, Tarrés-Freixas, Ferran, Aguilar-Gurrieri, Carmen, Carrillo, Jorge, Blanco, Julià, Gutiérrez-Granados, Sònia
Format: Article
Language:English
Subjects:
AIDS Vaccines - immunology
Analysis
Animals
Biomedical and Life Sciences
Bioreactors
Biotechnology
Clinical Trials as Topic
Genetic aspects
Genetic Vectors
Genomes
HIV
HIV (Viruses)
HIV-1
Human immunodeficiency virus
Humans
Identification and classification
Immunization
Insecta - genetics
Insects
Life Sciences
Mammalian cells
Mice
Microbial Genetics and Genomics
Microbiology
Mini-Review
Nuclease
Plants - genetics
Purification
Vaccines
Vaccines, Virus-Like Particle - biosynthesis
Vaccines, Virus-Like Particle - immunology
Vectors
Virus-like particles
Viruses
Yeast
Yeasts
Yeasts - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13
cites cdi_FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13
container_end_page 7384
container_issue 18
container_start_page 7367
container_title Applied microbiology and biotechnology
container_volume 103
creator Cervera, Laura
Gòdia, Francesc
Tarrés-Freixas, Ferran
Aguilar-Gurrieri, Carmen
Carrillo, Jorge
Blanco, Julià
Gutiérrez-Granados, Sònia
description Over the past years, much knowledge has been gained about the HIV-1 virus structure and infection cycle. This knowledge has been used to conceive different types of potential vaccines and vaccination strategies. This review focuses on the characteristics of the virus and the vaccines that have been developed, particularly on those using virus-like particles, as well as on the developments for their production and purification. The production of HIV-1 VLPs has been investigated in different platforms such as, yeast, plants, insect and mammalian cells. Their purification follows the same rational as for viral vectors: clarification, nuclease treatment, concentration/capture, polishing, formulation and viral clearance. Analytical techniques to characterise the obtained productions will be of paramount relevance for their final application, considering that the raw production obtained in bioreactors comprises not only the VLPs of interest but also many other extracellular vesicles. Finally, it should also be considered that VLPs are prone to carry host cell proteins and DNA.
doi_str_mv 10.1007/s00253-019-10038-3
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268309778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A597980553</galeid><sourcerecordid>A597980553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhoNY7Fr9A17IgDf2IjXfH96VYu1CoeLnZchkkjV1ZrImM4v-e7Pd1rIiJReHnDzvyTmHF4AXGJ1ghOSbghDhFCKsYb1TBekjsMCMEogEZo_BAmHJoeRaHYKnpVwjhIkS4gk4pJhKIhFdgG8fcupmN8U0Nik0F8uvEMPWFt81m5jnAvv4wzdrm6foel-akHKzsc7F0W41bxvrvke_8YMfp9LYsWv6OMSpPAMHwfbFP7-NR-DL-bvPZxfw8ur98uz0EjrO8ASDdVxyzB1q244xG7RlLcbMtq1UQgWPa5tacc0EUkTUjNJBScQUkgo7TI_A613ddU4_Z18mM8TifN_b0ae5GEKEokhLqSr66h_0Os15rN0ZIjSrC-FMPkgRIbnSgqB7amV7b-IY0pSt235tTrmWWiHOaaVO_kPV0_khujT6EGt-T3C8J6jM5H9NKzuXYpafPu6zZMe6nErJPph1joPNvw1GZusPs_OHqf4wN_4wW9HL2-nmdvDdX8mdISpAd0CpT-PK5_vxHyj7B2u0wEI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267589620</pqid></control><display><type>article</type><title>Production of HIV-1-based virus-like particles for vaccination: achievements and limits</title><source>ABI/INFORM Global</source><source>Springer Link</source><creator>Cervera, Laura ; Gòdia, Francesc ; Tarrés-Freixas, Ferran ; Aguilar-Gurrieri, Carmen ; Carrillo, Jorge ; Blanco, Julià ; Gutiérrez-Granados, Sònia</creator><creatorcontrib>Cervera, Laura ; Gòdia, Francesc ; Tarrés-Freixas, Ferran ; Aguilar-Gurrieri, Carmen ; Carrillo, Jorge ; Blanco, Julià ; Gutiérrez-Granados, Sònia</creatorcontrib><description>Over the past years, much knowledge has been gained about the HIV-1 virus structure and infection cycle. This knowledge has been used to conceive different types of potential vaccines and vaccination strategies. This review focuses on the characteristics of the virus and the vaccines that have been developed, particularly on those using virus-like particles, as well as on the developments for their production and purification. The production of HIV-1 VLPs has been investigated in different platforms such as, yeast, plants, insect and mammalian cells. Their purification follows the same rational as for viral vectors: clarification, nuclease treatment, concentration/capture, polishing, formulation and viral clearance. Analytical techniques to characterise the obtained productions will be of paramount relevance for their final application, considering that the raw production obtained in bioreactors comprises not only the VLPs of interest but also many other extracellular vesicles. Finally, it should also be considered that VLPs are prone to carry host cell proteins and DNA.</description><identifier>ISSN: 0175-7598</identifier><identifier>EISSN: 1432-0614</identifier><identifier>DOI: 10.1007/s00253-019-10038-3</identifier><identifier>PMID: 31372703</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>AIDS Vaccines - immunology ; Analysis ; Animals ; Biomedical and Life Sciences ; Bioreactors ; Biotechnology ; Clinical Trials as Topic ; Genetic aspects ; Genetic Vectors ; Genomes ; HIV ; HIV (Viruses) ; HIV-1 ; Human immunodeficiency virus ; Humans ; Identification and classification ; Immunization ; Insecta - genetics ; Insects ; Life Sciences ; Mammalian cells ; Mice ; Microbial Genetics and Genomics ; Microbiology ; Mini-Review ; Nuclease ; Plants - genetics ; Purification ; Vaccines ; Vaccines, Virus-Like Particle - biosynthesis ; Vaccines, Virus-Like Particle - immunology ; Vectors ; Virus-like particles ; Viruses ; Yeast ; Yeasts ; Yeasts - genetics</subject><ispartof>Applied microbiology and biotechnology, 2019-09, Vol.103 (18), p.7367-7384</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Applied Microbiology and Biotechnology is a copyright of Springer, (2019). All Rights Reserved.</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13</citedby><cites>FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13</cites><orcidid>0000-0002-3639-2793</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2267589620/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2267589620?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,11686,27922,27923,36058,36059,44361,74665</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31372703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cervera, Laura</creatorcontrib><creatorcontrib>Gòdia, Francesc</creatorcontrib><creatorcontrib>Tarrés-Freixas, Ferran</creatorcontrib><creatorcontrib>Aguilar-Gurrieri, Carmen</creatorcontrib><creatorcontrib>Carrillo, Jorge</creatorcontrib><creatorcontrib>Blanco, Julià</creatorcontrib><creatorcontrib>Gutiérrez-Granados, Sònia</creatorcontrib><title>Production of HIV-1-based virus-like particles for vaccination: achievements and limits</title><title>Applied microbiology and biotechnology</title><addtitle>Appl Microbiol Biotechnol</addtitle><addtitle>Appl Microbiol Biotechnol</addtitle><description>Over the past years, much knowledge has been gained about the HIV-1 virus structure and infection cycle. This knowledge has been used to conceive different types of potential vaccines and vaccination strategies. This review focuses on the characteristics of the virus and the vaccines that have been developed, particularly on those using virus-like particles, as well as on the developments for their production and purification. The production of HIV-1 VLPs has been investigated in different platforms such as, yeast, plants, insect and mammalian cells. Their purification follows the same rational as for viral vectors: clarification, nuclease treatment, concentration/capture, polishing, formulation and viral clearance. Analytical techniques to characterise the obtained productions will be of paramount relevance for their final application, considering that the raw production obtained in bioreactors comprises not only the VLPs of interest but also many other extracellular vesicles. Finally, it should also be considered that VLPs are prone to carry host cell proteins and DNA.</description><subject>AIDS Vaccines - immunology</subject><subject>Analysis</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Bioreactors</subject><subject>Biotechnology</subject><subject>Clinical Trials as Topic</subject><subject>Genetic aspects</subject><subject>Genetic Vectors</subject><subject>Genomes</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Immunization</subject><subject>Insecta - genetics</subject><subject>Insects</subject><subject>Life Sciences</subject><subject>Mammalian cells</subject><subject>Mice</subject><subject>Microbial Genetics and Genomics</subject><subject>Microbiology</subject><subject>Mini-Review</subject><subject>Nuclease</subject><subject>Plants - genetics</subject><subject>Purification</subject><subject>Vaccines</subject><subject>Vaccines, Virus-Like Particle - biosynthesis</subject><subject>Vaccines, Virus-Like Particle - immunology</subject><subject>Vectors</subject><subject>Virus-like particles</subject><subject>Viruses</subject><subject>Yeast</subject><subject>Yeasts</subject><subject>Yeasts - genetics</subject><issn>0175-7598</issn><issn>1432-0614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNp9kl1rFDEUhoNY7Fr9A17IgDf2IjXfH96VYu1CoeLnZchkkjV1ZrImM4v-e7Pd1rIiJReHnDzvyTmHF4AXGJ1ghOSbghDhFCKsYb1TBekjsMCMEogEZo_BAmHJoeRaHYKnpVwjhIkS4gk4pJhKIhFdgG8fcupmN8U0Nik0F8uvEMPWFt81m5jnAvv4wzdrm6foel-akHKzsc7F0W41bxvrvke_8YMfp9LYsWv6OMSpPAMHwfbFP7-NR-DL-bvPZxfw8ur98uz0EjrO8ASDdVxyzB1q244xG7RlLcbMtq1UQgWPa5tacc0EUkTUjNJBScQUkgo7TI_A613ddU4_Z18mM8TifN_b0ae5GEKEokhLqSr66h_0Os15rN0ZIjSrC-FMPkgRIbnSgqB7amV7b-IY0pSt235tTrmWWiHOaaVO_kPV0_khujT6EGt-T3C8J6jM5H9NKzuXYpafPu6zZMe6nErJPph1joPNvw1GZusPs_OHqf4wN_4wW9HL2-nmdvDdX8mdISpAd0CpT-PK5_vxHyj7B2u0wEI</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Cervera, Laura</creator><creator>Gòdia, Francesc</creator><creator>Tarrés-Freixas, Ferran</creator><creator>Aguilar-Gurrieri, Carmen</creator><creator>Carrillo, Jorge</creator><creator>Blanco, Julià</creator><creator>Gutiérrez-Granados, Sònia</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>LK8</scope><scope>M0C</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3639-2793</orcidid></search><sort><creationdate>20190901</creationdate><title>Production of HIV-1-based virus-like particles for vaccination: achievements and limits</title><author>Cervera, Laura ; Gòdia, Francesc ; Tarrés-Freixas, Ferran ; Aguilar-Gurrieri, Carmen ; Carrillo, Jorge ; Blanco, Julià ; Gutiérrez-Granados, Sònia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>AIDS Vaccines - immunology</topic><topic>Analysis</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Bioreactors</topic><topic>Biotechnology</topic><topic>Clinical Trials as Topic</topic><topic>Genetic aspects</topic><topic>Genetic Vectors</topic><topic>Genomes</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Immunization</topic><topic>Insecta - genetics</topic><topic>Insects</topic><topic>Life Sciences</topic><topic>Mammalian cells</topic><topic>Mice</topic><topic>Microbial Genetics and Genomics</topic><topic>Microbiology</topic><topic>Mini-Review</topic><topic>Nuclease</topic><topic>Plants - genetics</topic><topic>Purification</topic><topic>Vaccines</topic><topic>Vaccines, Virus-Like Particle - biosynthesis</topic><topic>Vaccines, Virus-Like Particle - immunology</topic><topic>Vectors</topic><topic>Virus-like particles</topic><topic>Viruses</topic><topic>Yeast</topic><topic>Yeasts</topic><topic>Yeasts - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cervera, Laura</creatorcontrib><creatorcontrib>Gòdia, Francesc</creatorcontrib><creatorcontrib>Tarrés-Freixas, Ferran</creatorcontrib><creatorcontrib>Aguilar-Gurrieri, Carmen</creatorcontrib><creatorcontrib>Carrillo, Jorge</creatorcontrib><creatorcontrib>Blanco, Julià</creatorcontrib><creatorcontrib>Gutiérrez-Granados, Sònia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>Biological Sciences</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Applied microbiology and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cervera, Laura</au><au>Gòdia, Francesc</au><au>Tarrés-Freixas, Ferran</au><au>Aguilar-Gurrieri, Carmen</au><au>Carrillo, Jorge</au><au>Blanco, Julià</au><au>Gutiérrez-Granados, Sònia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Production of HIV-1-based virus-like particles for vaccination: achievements and limits</atitle><jtitle>Applied microbiology and biotechnology</jtitle><stitle>Appl Microbiol Biotechnol</stitle><addtitle>Appl Microbiol Biotechnol</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>103</volume><issue>18</issue><spage>7367</spage><epage>7384</epage><pages>7367-7384</pages><issn>0175-7598</issn><eissn>1432-0614</eissn><abstract>Over the past years, much knowledge has been gained about the HIV-1 virus structure and infection cycle. This knowledge has been used to conceive different types of potential vaccines and vaccination strategies. This review focuses on the characteristics of the virus and the vaccines that have been developed, particularly on those using virus-like particles, as well as on the developments for their production and purification. The production of HIV-1 VLPs has been investigated in different platforms such as, yeast, plants, insect and mammalian cells. Their purification follows the same rational as for viral vectors: clarification, nuclease treatment, concentration/capture, polishing, formulation and viral clearance. Analytical techniques to characterise the obtained productions will be of paramount relevance for their final application, considering that the raw production obtained in bioreactors comprises not only the VLPs of interest but also many other extracellular vesicles. Finally, it should also be considered that VLPs are prone to carry host cell proteins and DNA.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31372703</pmid><doi>10.1007/s00253-019-10038-3</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-3639-2793</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0175-7598
ispartof Applied microbiology and biotechnology, 2019-09, Vol.103 (18), p.7367-7384
issn 0175-7598
1432-0614
language eng
recordid cdi_proquest_miscellaneous_2268309778
source ABI/INFORM Global; Springer Link
subjects AIDS Vaccines - immunology
Analysis
Animals
Biomedical and Life Sciences
Bioreactors
Biotechnology
Clinical Trials as Topic
Genetic aspects
Genetic Vectors
Genomes
HIV
HIV (Viruses)
HIV-1
Human immunodeficiency virus
Humans
Identification and classification
Immunization
Insecta - genetics
Insects
Life Sciences
Mammalian cells
Mice
Microbial Genetics and Genomics
Microbiology
Mini-Review
Nuclease
Plants - genetics
Purification
Vaccines
Vaccines, Virus-Like Particle - biosynthesis
Vaccines, Virus-Like Particle - immunology
Vectors
Virus-like particles
Viruses
Yeast
Yeasts
Yeasts - genetics
title Production of HIV-1-based virus-like particles for vaccination: achievements and limits
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A29%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Production%20of%20HIV-1-based%20virus-like%20particles%20for%20vaccination:%20achievements%20and%20limits&rft.jtitle=Applied%20microbiology%20and%20biotechnology&rft.au=Cervera,%20Laura&rft.date=2019-09-01&rft.volume=103&rft.issue=18&rft.spage=7367&rft.epage=7384&rft.pages=7367-7384&rft.issn=0175-7598&rft.eissn=1432-0614&rft_id=info:doi/10.1007/s00253-019-10038-3&rft_dat=%3Cgale_proqu%3EA597980553%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c541t-fac57515c0bbd44af9a4b114abb7868fe1270985946082668f89f870480781c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2267589620&rft_id=info:pmid/31372703&rft_galeid=A597980553&rfr_iscdi=true